查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587504

抗菌素抗藥性診斷市場規模、佔有率、趨勢分析報告：按技術、最終用途、病原體、地區、細分市場預測，2025-2030 年

Antimicrobial Resistance Diagnostics Market Size, Share & Trends Analysis Report By Technology (Microbiology Culture, PCR), By End-use (Hospitals, Diagnostic Laboratories), By Pathogen, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

抗生素抗藥性診斷市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球抗菌藥物抗藥性診斷市場規模預計將達到67億美元，2025年至2030年複合年成長率為6.55%。

抗藥性病菌感染的風險不斷增加，特別是在醫療機構中，以及政府和非政府組織加強應對抗菌素抗藥性威脅，是推動市場成長的關鍵因素。此外，主要市場參與者為管理抗菌素抗藥性所採取的各種策略舉措也有助於市場擴張。例如，2021年3月，生物梅里埃與GIZ聯合支持奈及利亞疾病管制中心加強對抗抗菌素抗藥性。

由於擴大採用快速檢測和 PoC 檢測來檢測抗藥性細菌感染疾病，預計該市場將在預測期內擴大。此外，丹納赫和雅培等領先的市場參與者擁有強大的抗生素抗藥性病菌感染快速診斷測試產品系列。此外，AMR 行業聯盟等非政府組織的日益參與正在幫助監管機構制定策略，促進診斷解決方案的開發，以管理抗菌素抗藥性。

增加用於開發用於診斷抗菌藥物抗藥性感染疾病的新型自動化測試解決方案的資金籌措預計將在預測期內推動市場成長。例如，2022年5月，歐洲投資銀行向POCARED Diagnostics提供超過2,400萬美元資金，用於微生物疾病全自動檢測的研發。 POCARED Diagnostics 參與開發新的微生物測試，可在數小時內提供結果。

預計未來幾年抗菌藥物抗藥性將會增加。因此，為了有效管理和監測抗菌藥物抗藥性的進展，對準確、快速檢測方案的需求預計將會增加。據CDC稱，美國每年因抗菌藥物抗藥性造成的直接醫療費用約為200億美元。

新興市場的主要參與者正在不斷努力開拓新的測試，以鞏固其市場地位。此外，主要企業也採取收購、聯盟、合作等其他策略來擴大產品系列。例如，2022 年 8 月，Accelerate Diagnostics 和 BD 宣布合作應對抗菌素抗藥性的威脅。透過這項協議，BD 將向 Accelerate Diagnostics 龐大的客戶群提供抗生素相關抗藥性的快速診斷解決方案。

抗菌素抗藥性診斷市場報告亮點

  • PCR領域佔市場主導地位，2024年收益佔有率最大，為24.19%。 PCR 技術的進步及其由於其高精度而廣泛採用，是推動該細分市場佔據較大佔有率的主要因素。
  • 2024年，抗藥性金黃色葡萄球菌細分市場佔據最大市場佔有率，達28.33%。醫院環境中 MRSA 發生率的增加是該細分市場擴張的主要驅動力。
  • 2024年，醫院細分市場領先，佔銷售佔有率的48.07%。此細分市場的成長受到多種因素的推動，包括醫院感染發生率上升以及抗菌素抗藥性 (AMR) 感染導致的住院人數增加。
  • 北美抗菌素抗藥性診斷市場在全球整體市場中佔據主導地位，2024年收益佔有率為42.03%。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章抗菌素抗藥性診斷市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 抗菌素抗藥性診斷市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章抗生素抗藥性診斷市場：技術估算與趨勢分析

  • 細分儀表板
  • 抗生素抗藥性診斷市場：技術變化分析
  • 抗菌素抗藥性診斷市場：技術展望
  • 2018-2030年市場規模、預測及趨勢分析
  • 微生物學培養
  • 免疫檢測
    • PCR
    • 下一代種子
    • 質譜分析
    • 快速照護現場
    • 其他

第5章抗菌藥物抗藥性診斷市場：按病原體估計和趨勢分析

  • 細分儀表板
  • 抗菌藥物抗藥性診斷市場：病原體變異分析
  • 按病原體分類的抗生素抗藥性診斷市場前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 抗藥性肺炎鏈球菌 (DRSP)
  • 抗藥性彎曲曲狀桿菌(DRC)
  • 困難梭狀芽孢桿菌(CD)
  • 抗藥性淋病 (DRNG)
  • 抗藥性沙門氏菌 (DRNTS)
  • 其他

第6章抗菌素抗藥性診斷市場：最終用途的估計和趨勢分析

  • 細分儀表板
  • 抗菌素抗藥性診斷市場：最終用途變異分析
  • 按最終用途分類的抗菌素抗藥性診斷市場前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 醫院
  • 診斷實驗室
  • 製藥和生物技術公司
  • 其他

第7章抗生素抗藥性診斷市場：區域估計與趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 市場參與企業分類
  • 主要市場參與企業的最新趨勢和影響分析
  • 2024 年企業市場佔有率分析
  • 主要企業簡介
    • bioMerieux
    • F. Hoffmann-La Roche Ltd
    • Abbott
    • BD
    • Danaher
    • Accelerate Diagnostics, Inc.
    • Molsid
    • Vela Diagnostics
    • Visby Medical, Inc.
    • Hologic, Inc.
Product Code: GVR-4-68039-990-4

Antimicrobial Resistance Diagnostics Market Growth & Trends:

The global antimicrobial resistance diagnostics market size is expected to reach USD 6.70 billion by 2030, registering a CAGR of 6.55% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increased risk of developing drug-resistant bacterial infections, especially in healthcare facilities, and increasing government & non-government bodies' efforts to combat the threat of AMR are the major factor contributing to market growth. In addition, various strategic initiatives undertaken by leading market players to manage antimicrobial resistance are also contributing to market expansion. For instance, in March 2021, bioMerieux and GIZ collaborated to support the Nigerian center for disease control to strengthen the fight against AMR.

The rising adoption of rapid testing and PoC tests for drug-resistant bacterial infections is anticipated to augment the market over the projected period. Moreover, leading market players such as Danaher, Abbott, and others have a robust product portfolio of rapid diagnostic tests for antimicrobial-resistant infections. Furthermore, the increasing involvement of non-government bodies such as AMR Industry Alliance is assisting regulatory bodies to make strategies to boost the development of diagnostic solutions to manage antimicrobial resistance.

Increasing funding for the development of novel and automated test solutions for the diagnosis of antimicrobial-resistant infections is anticipated to boost market growth over the forecast period. For instance, in May 2022, the European Investment Bank funded more than USD 24 million to POCARED Diagnostics for the R&D of fully automated testing of microbial diseases. POCARED Diagnostics is involved in the development of novel microbiology tests that can provide results within hours.

Antimicrobial resistance is expected to rise in the coming years. Hence, demand for accurate & fast testing options is expected to increase for the effective management and progression monitoring of antimicrobial resistance. According to the CDC, the annual direct healthcare expenditure of antimicrobial resistance is around USD 20 billion in the U.S. High cost of disease management is driving the demand for rapid tests for the diagnosis of infections at an early stage.

Key market players are continuously involved in the development of novel tests to strengthen their market position. Moreover, other strategies such as acquisitions, partnerships, and collaborations are also adopted by leading players to expand their product portfolio in different parts of the globe. For instance, in August 2022, Accelerate Diagnostics and BD announced a collaboration to combat the threat of antimicrobial resistance. As per the deal, BD will provide Accelerate Diagnostics rapid diagnostic solutions for antibiotics-associated resistance to its vast customers.

Antimicrobial Resistance Diagnostics Market Report Highlights:

  • The PCR segment dominated the market and accounted for the largest revenue share of 24.19% in 2024. Advancements in PCR technology, along with its widespread adoption due to its high accuracy, are key factors driving the significant share of this segment.
  • In 2024, the methicillin resistant staphylococcus aureus segment held the largest market share at 28.33%. The rising incidence of MRSA in hospital settings is a key driver for the expansion of this segment.
  • In 2024, the hospitals segment led the market, accounting for 48.07% of the revenue share. The growth of this segment is driven by several factors, including the rising incidence of hospital-acquired infections and increased hospitalizations due to antimicrobial-resistant (AMR) infections, which often lead to prolonged hospital stays.
  • North America antimicrobial resistance diagnostics market dominated the overall global market with a revenue share of 42.03% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technology
    • 1.2.2. Pathogen
    • 1.2.3. End Use
    • 1.2.4. Regional Scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Antimicrobial Resistance Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increase in risk of developing drug - resistant bacterial infections
      • 3.2.1.2. Introduction of novel technologies to diagnose AMR infections
      • 3.2.1.3. Favorable government initiatives
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Presence of stringent rules and regulations pertaining to diagnostics
  • 3.3. Antimicrobial Resistance Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Antimicrobial Resistance Diagnostics Market: Technology Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Antimicrobial Resistance Diagnostics Market: Technology Movement Analysis
  • 4.3. Antimicrobial Resistance Diagnostics Market by Technology Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Microbiology Culture
    • 4.5.1. Microbiology Culture Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Immunoassay
    • 4.6.1. Immunoassay Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.2. PCR
      • 4.6.2.1. PCR Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.3. NGS
      • 4.6.3.1. NGS Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.4. Mass Spectrometry
      • 4.6.4.1. Mass Spectrometry Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.5. Rapid & Point of Care
      • 4.6.5.1. Rapid & Point of Care Assays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.6. Others
      • 4.6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Antimicrobial Resistance Diagnostics Market: Pathogen Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Antimicrobial Resistance Diagnostics Market: Pathogen Movement Analysis
  • 5.3. Antimicrobial Resistance Diagnostics Market by Pathogen Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Drug Resistant Streptococcus Pneumoniae (DRSP)
    • 5.5.1. Drug Resistant Streptococcus Pneumoniae (DRSP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Drug Resistant Campylobacter (DRC)
    • 5.6.1. Drug Resistant Campylobacter (DRC) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Clostridium Difficile (CD)
    • 5.7.1. Clostridium Difficile (CD) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Drug Resistant Neisseria Gonorrhoeae (DRNG)
    • 5.8.1. Drug Resistant Neisseria Gonorrhoeae (DRNG) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Drug Resistant Salmonella (DRNTS)
    • 5.9.1. Drug Resistant Salmonella (DRNTS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.10. Others
    • 5.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Antimicrobial Resistance Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Antimicrobial Resistance Diagnostics Market: End Use Movement Analysis
  • 6.3. Antimicrobial Resistance Diagnostics Market by End Use Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Hospitals
    • 6.5.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Diagnostic Laboratories
    • 6.6.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Pharmaceutical & Biotechnology Companies
    • 6.7.1. Pharmaceutical & Biotechnology Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Antimicrobial Resistance Diagnostics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Recent Developments & Impact Analysis by Key Market Participants
  • 8.3. Company Market Share Analysis, 2024
  • 8.4. Key Company Profiles
    • 8.4.1. bioMerieux
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. F. Hoffmann - La Roche Ltd
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Abbott
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. BD
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Danaher
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Accelerate Diagnostics, Inc.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Molsid
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Vela Diagnostics
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Visby Medical, Inc.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Hologic, Inc.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 4 Global Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 5 Global Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 6 North America Antimicrobial Resistance Diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 7 North America Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 8 North America Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 9 North America Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 10 U.S Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 11 U.S Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 12 U.S Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 13 Mexico Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 14 Mexico Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 15 Mexico Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 16 Canada Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 17 Canada Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 18 Canada Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 19 Europe Antimicrobial Resistance Diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 20 Europe Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 21 Europe Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 22 Europe Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 23 UK Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 24 UK Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 25 UK Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 26 Germany Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 27 Germany Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 28 Germany Antimicrobial Resistance Diagnostics market, by End Use 2018 - 2030 (USD Million)
  • Table 29 France Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 30 France Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 31 France Antimicrobial Resistance Diagnostics market, by End Use 2018 - 2030 (USD Million)
  • Table 32 Italy Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 33 Italy Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 34 Italy Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 35 Spain Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 36 Spain Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 37 Spain Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 38 Denmark Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 39 Denmark Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 40 Denmark Antimicrobial Resistance Diagnostics market, by End Use 2018 - 2030 (USD Million)
  • Table 41 Norway Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 42 Norway Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 43 Norway Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 44 Sweden Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 45 Sweden Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 46 Sweden Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Antimicrobial Resistance Diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 51 Japan Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 52 Japan Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 53 Japan Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 54 China Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 55 China Antimicrobial Resistance Diagnostics market, by Pathogen 2018 - 2030 (USD Million)
  • Table 56 China Antimicrobial Resistance Diagnostics market, by End Use 2018 - 2030 (USD Million)
  • Table 57 India Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 58 India Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 59 India Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 60 Australia Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 61 Australia Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 62 Australia Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 63 South Korea Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 64 South Korea Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 65 South Korea Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 66 Thailand Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 67 Thailand Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 68 Thailand Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 69 Latin America Antimicrobial Resistance Diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 70 Latin America Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 71 Latin America Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 72 Latin America Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 73 Brazil Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 74 Brazil Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 75 Brazil Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 76 Argentina Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 77 Argentina Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 78 Argentina Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Antimicrobial Resistance Diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 83 South Africa Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 84 South Africa Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 85 South Africa Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 89 UAE Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 90 UAE Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 91 UAE Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 Antimicrobial Resistance Diagnostics market segmentation
  • Fig. 7 Market driver analysis (current & future impact)
  • Fig. 8 Market restraint analysis (current & future impact)
  • Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 10 Porter's five forces analysis
  • Fig. 11 Antimicrobial resistance diagnostics market, Technology outlook key takeaways, 2024 & 2030 (USD Million)
  • Fig. 12 Antimicrobial resistance diagnostics market: Pathogen movement analysis, 2024 & 2030 (USD Million)
  • Fig. 13 Antimicrobial resistance diagnostics market: end use movement analysis, 2024 & 2030 (USD Million)
  • Fig. 14 Microbiology Culture market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 Immunoassay market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 PCR market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 NGS market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Mass Spectrometry market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Rapid & Point of Care market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Drug Resistant Streptococcus Pneumoniae market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Drug Resistant Campylobacter market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Clostridium Difficile market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Methicillin Resistant Staphylococcus Aureus market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Drug Resistant Neisseria Gonorrhoeae market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Drug Resistant Salmonella market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Hospitals market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Diagnostic Laboratories market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Pharmaceutical & Biotechnology Companies market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 North America antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 US antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Canada antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Mexico antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Europe antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 UK antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Germany antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 France antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Spain antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Italy antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Norway antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Denmark antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Sweden antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Asia Pacific antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 China antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Japan antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 India antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 South Korea antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Australia antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Thailand antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Latin America antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Brazil antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Argentina antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Middle East and Africa antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 South Africa antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Saudi Arabia antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 UAE antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Kuwait antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 List of key emerging company's/Allergen disruptors/innovators